2.39

6.64% -0.17

After Hours: 2.39

Acumen Pharmaceuticals Inc (ABOS)

Overview News Price History Option Chain Financials Discussions Forecast

Acumen Pharmaceuticals Inc stock is traded at $2.39, with a volume of 261.58K. It is down -6.64% in the last 24 hours and up +38.95% over the past month. Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Previous Close:

$2.56

Open:

$2.57

24h Volume:

261.58K

Relative Volume:

0.49

Market Cap:

$144.77M

Revenue:

Net Income/Loss:

$-64.86M

P/E Ratio:

-2.1339

EPS:

-1.12

Net Cash Flow:

$-55.66M

1W Performance:

+6.22%

1M Performance:

+38.95%

6M Performance:

+89.68%

1Y Performance:

+74.45%

1-Day Range:

$2.34

$2.57

1-Week Range:

$2.2501

$2.58

52-Week Range:

$0.8551

$3.0499

Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile

Name

Acumen Pharmaceuticals Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

617-344-4190

Address

1210-1220 WASHINGTON STREET, NEWTON

Employee

Twitter

Next Earnings Date

2025-03-31

Latest SEC Filings

ABOS's Discussions on Twitter

Compare ABOS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ABOS Acumen Pharmaceuticals Inc	2.39	155.07M	0	-64.86M	-55.66M	-1.12
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-17-25	Initiated	Citigroup	Buy
Jul-26-24	Initiated	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-20-23	Resumed	BofA Securities	Buy
May-18-23	Initiated	Cantor Fitzgerald	Overweight
Jul-15-22	Initiated	BTIG Research	Buy
Jun-30-22	Initiated	H.C. Wainwright	Buy
Jan-21-22	Upgrade	BofA Securities	Neutral → Buy
Jul-26-21	Initiated	BofA Securities	Neutral
Jul-26-21	Initiated	Credit Suisse	Outperform
Jul-26-21	Initiated	Stifel	Buy
Jul-26-21	Initiated	UBS	Buy

View All

Acumen Pharmaceuticals Inc Stock (ABOS) Latest News

Feb 09, 2026

Acumen Pharmaceuticals celebrates team contributions - Traders Union

Feb 09, 2026

Feb 08, 2026

Brokerages Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Price Target at $6.80 - Defense World

Feb 08, 2026

Feb 05, 2026

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Feb 05, 2026

Feb 03, 2026

Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail

Feb 03, 2026

Jan 31, 2026

Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Lowered to Sell at Wall Street Zen - MarketBeat

Jan 31, 2026

Jan 29, 2026

While Institutions Invested in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Benefited From Last Week's 46% Gain, Private Equity Firms Stood to Gain the Most - 富途牛牛

Jan 29, 2026

Jan 28, 2026

Acumen Pharma CLO sells $53k in shares after option exercise - Investing.com Canada

Jan 28, 2026

Healthcare Stocks Surge in After-Hours Trading - intellectia.ai

Jan 28, 2026

Jan 27, 2026

Wall Street Analysts Adjust Ratings - intellectia.ai

Jan 27, 2026

Assessing Acumen Pharmaceuticals (ABOS) Valuation After New Phase 2 ALTITUDE-AD Trial Developments - Yahoo Finance

Jan 27, 2026

Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Raised to $7.00 at BTIG Research - MarketBeat

Jan 27, 2026

Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - Sahm

Jan 27, 2026

Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Jan 27, 2026

ABOS: BTIG Raises Price Target to $7.00, Maintains Buy Rating | - GuruFocus

Jan 27, 2026

Jan 26, 2026

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Jan 26, 2026

Acumen Pharmaceuticals’ Share Volatility: Insight Into Recent Developments - StocksToTrade

Jan 26, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Jan 26, 2026

Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance

Jan 26, 2026

Jan 24, 2026

Acumen Pharmaceuticals CEO sells shares worth $21993 By Investing.com - Investing.com Nigeria

Jan 24, 2026

Acumen Pharmaceuticals CLO sells shares worth $16,720 By Investing.com - Investing.com South Africa

Jan 24, 2026

Jan 23, 2026

Acumen Pharma CFO Zuga sells shares worth $7.6k By Investing.com - Investing.com Canada

Jan 23, 2026

Acumen Pharmaceuticals CEO sells shares worth $21993 - Investing.com

Jan 23, 2026

Daniel Joseph Oconnell Sells 9,346 Shares of Acumen Pharmaceuticals (NASDAQ:ABOS) Stock - MarketBeat

Jan 23, 2026

Acumen Pharmaceuticals CLO sells shares worth $16,720 - Investing.com

Jan 23, 2026

Acumen Pharma CMO Siemers sells $5.8k in ABOS stock By Investing.com - Investing.com UK

Jan 23, 2026

Jan 20, 2026

"Study Within A Study" Reveals Best Recruitment Strategies For Alzheimer's Trials - Clinical Leader

Jan 20, 2026

Jan 19, 2026

January 2026's Rising Stars: Top Penny Stocks To Watch - simplywall.st

Jan 19, 2026

Jan 18, 2026

VIX Spike: How does Acumen Pharmaceuticals Inc perform in inflationary periods2025 Technical Overview & Smart Swing Trading Techniques - baoquankhu1.vn

Jan 18, 2026

Jan 14, 2026

EV Market: What is the earnings history of Acumen Pharmaceuticals IncQuarterly Performance Summary & Low Drawdown Momentum Ideas - baoquankhu1.vn

Jan 14, 2026